- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05159245
L'étude nationale finlandaise visant à faciliter l'accès des patients à des médicaments anticancéreux ciblés (FINPROVE)
L'étude nationale finlandaise visant à faciliter l'accès des patients à des médicaments anticancéreux ciblés afin de déterminer l'efficacité du traitement des cancers avancés avec un profil moléculaire connu
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Médicament: Alectinib
- Médicament: Cobimetinib
- Médicament: Vismodegib
- Médicament: Trastuzumab+Pertuzumab
- Médicament: Entrectinib
- Médicament: Atezolizumab
- Médicament: Vemurafenib
- Médicament: Regorafenib
- Médicament: Apalutamide
- Médicament: Abemaciclib
- Médicament: Tepotinib
- Médicament: Dabrafenib
- Médicament: Trametinib
- Médicament: Dabrafenib+Trametinib
- Médicament: Pemigatinib
Description détaillée
This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Tanja Juslin
- Numéro de téléphone: +358405597415
- E-mail: tanja.juslin@hus.fi
Lieux d'étude
-
-
-
Kuopio, Finlande
- Recrutement
- Kuopio University Hospital
-
Contact:
- Okko Kääriäinen, MD
-
Oulu, Finlande
- Recrutement
- Oulu University Hospital OYS Cancer Center
-
Contact:
- Sanna Iivanainen, MD. PhD.
-
Tampere, Finlande
- Recrutement
- Tampere University Hospital Department of Oncology
-
Contact:
- Minna Tanner, MD, PhD
-
-
Southwest Finland
-
Turku, Southwest Finland, Finlande
- Recrutement
- Turku University Hospital Cancer Centre
-
Contact:
- Erika Alanne, MD, PhD
-
-
Uusimaa
-
Helsinki, Uusimaa, Finlande, 00029
- Recrutement
- Helsinki University Hospital Comprehensive Cancer Center
-
Contact:
- Tanja Juslin
-
Chercheur principal:
- Katriina Jalkanen, MD, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.
-
ECOG performance status 0-2
-
Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:
- Absolute neutrophil count ≥ 1.5 x 109/l
- Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
- Platelets > 75 x 109/l (not applicable for hematological patients)
- Total bilirubin < 1.5 x ULN
- AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
-
Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.
-
Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.
-
Patients must have a tumor profile for which treatment with one of the approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.
-
A new (obtained ≤6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.
-
Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.
Exclusion Criteria:
-
Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.
-
Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:
- Patients suffering from CRPC are allowed to continue androgen deprivation therapy.
- Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.
-
Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention
-
Patient is pregnant or nursing.
-
Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation. GMB patients apply additional exclusion criteria.
-
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.
-
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.
-
Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible
-
Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible
-
Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Alectinib
For patients with a molecular tumor profile that can potentially be targeted by alectinib. |
ALK
Autres noms:
|
|
Expérimental: Cobimetinib
For patients with a molecular tumor profile that can potentially be targeted by cobimetinib. |
MEK1, MEK2
Autres noms:
|
|
Expérimental: Vismodegib
For patients with a molecular tumor profile that can potentially be targeted by vismodegib. |
Hedgehog
Autres noms:
|
|
Expérimental: Trastuzumab+Pertuzumab
For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination. |
HER2
Autres noms:
|
|
Expérimental: Entrectinib
For patients with a molecular tumor profile that can potentially be targeted by entrectinib. |
NTRK/ ROS1, ALK
Autres noms:
|
|
Expérimental: Atezolizumab
For patients with a molecular tumor profile that can potentially be targeted by atezolizumab. |
PD-L1
Autres noms:
|
|
Expérimental: Vemurafenib
For patients with a molecular tumor profile that can potentially be targeted by vemurafenib. |
BRAF V600
Autres noms:
|
|
Expérimental: Regorafenib
For patients with a molecular tumor profile that can potentially be targeted by regorafenib. |
KIT/BRAF, RET
Autres noms:
|
|
Expérimental: Apalutamide
For patients with a molecular tumor profile that can potentially be targeted by apalutamide. |
AR
Autres noms:
|
|
Expérimental: Abemaciclib
For patients with a molecular tumor profile that can potentially be targeted by abemaciclib. |
CDK4/6
Autres noms:
|
|
Expérimental: Tepotinib
For patients with a molecular tumor profile that can potentially be targeted by tepotinib. |
MET ex14
Autres noms:
|
|
Expérimental: Dabrafenib
For patients with a molecular tumor profile that can potentially be targeted by dabrafenib. |
RAF
Autres noms:
|
|
Expérimental: Trametinib
For patients with a molecular tumor profile that can potentially be targeted by trametinib. |
MEK1, MEK2
Autres noms:
|
|
Expérimental: Dabrafenib+Trametinib
For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination. |
RAF, MEK1, MEK2
Autres noms:
|
|
Expérimental: Pemigatinib
For patients with a molecular tumor profile that can potentially be targeted by pemigatinib. |
FGFR2
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disease control rate
Délai: 16 weeks
|
Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD) |
16 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Duration of treatment
Délai: 5 years
|
Time on drug |
5 years
|
|
Adverse Events
Délai: 5 years
|
Treatment-related grade ≥3 and serious adverse events |
5 years
|
|
Overall response
Délai: 5 years
|
Best overall response (defined as patients by CR, PR, SD) |
5 years
|
|
PFS
Délai: 5 years
|
Progression free survival |
5 years
|
|
OS
Délai: 5 years
|
Overall survival |
5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Katriina Jalkanen, MD, PhD, Helsinki University Hospital Comprehensive Cancer Centre
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies hématologiques
- Maladies hémiques et lymphatiques
- Tumeurs hématologiques
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Amides
- Indoles
- Sulfonamides
- Sulfones
- Vémurafénib
- abemaciclib
- dabrafenib
- trametinib
- atézolizumab
- cobimétinib
- régorafenib
- entrave
- pemigatinib
- alectinib
- apalutamide
- Hhantag691
- tepotinib
Autres numéros d'identification d'étude
- FINPROVE
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Investigators plan to share the clinical study report.
Délai de partage IPD
2026-2027
Critères d'accès au partage IPD
Will be made available through European regulatory CTIS programme.
Type d'informations de prise en charge du partage d'IPD
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .